RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RAPT)

CUSIP: 75382E109

Q4 2021 13F Holders as of 31 Dec 2021

Holder snapshot 7 signals
Share change
+1,509,925
Put/Call ratio
3.6%
SEC-reported price per share
$36.73
Number of holders
96
Value change
+$58,612,650
Number of buys
40
Open additional details 1 more signal available
Number of sells
53
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
27,725,634

Security key

75382E109

Report period

Q4 2021

Institutions

96

Top holders

10

Ownership snapshot

Top reported holders of RAPT - RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Peter Svennilson
Disclosed value leader
PRICE T ROWE ASSOCIATES I...
Comparable rows
0/15
Latest evidence
30 Sep 2021
3/4/5 13F Highest disclosed value: $121,163,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

PRICE T ROWE ASSOCIATES INC /MD/ has the largest disclosed position value at $121.16M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens PRICE T ROWE ASSOCIATES INC /MD/'s linked filing trail.
Disclosed position value Top 5
Peter Svennilson $56.8K
PRICE T ROWE ASSOCIATES INC /MD/ $121.16M
PERCEPTIVE ADVISORS LLC $90.28M
BlackRock Finance, Inc. $58.96M
Ponoi Management, LLC $49.66M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Peter Svennilson
3/4/5
Director, 10%+ Owner
—
denominator unverified
$56,850
7,500 shares
— 28 May 2021
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
—
denominator unverified
$121,163,000
3,902,178 shares
— 30 Sep 2021
PERCEPTIVE ADVISORS LLC
13F
Company
13F
—
denominator unverified
$90,280,000
2,907,565 shares
— 30 Sep 2021
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$58,957,000
1,898,821 shares
— 30 Sep 2021
Ponoi Management, LLC
13F
Company
13F
—
denominator unverified
$49,662,000
1,599,417 shares
— 30 Sep 2021
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
—
denominator unverified
$46,798,000
1,507,203 shares
— 30 Sep 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
96
Shares
26,299,986
Rows available
96
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2021 vs Q4 2025 Across Filers

Q4 2025 holders
3
Q4 2021 holders
96
Holder diff
93
Investor Q4 2025 Shares Q4 2021 Shares Share Diff Share Chg % Q4 2025 value Q4 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .